Dementia/Alzheimer Disease
RSSArticles
-
Wildfire Smoke Exposure Is a Risk Factor for Dementia
In this large, open cohort study based on electronic health record data from 2009 to 2019 of dementia-free people older than 60 years of age, exposure to wildfire smoke was shown to result in an increased incidence of dementia later in life.
-
Post-Traumatic Epilepsy and the Risk of Dementia
A subset of people with head injury will develop post-traumatic epilepsy (PTE). This prospective cohort study demonstrated a 4.5-fold increased risk of dementia in those with PTE compared to people without head trauma or epilepsy, and that this risk exceeds that observed in people with head trauma or epilepsy alone.
-
Blood Biomarker for the Diagnosis of Alzheimer’s Disease
In this population-based study of patients in Sweden with cognitive complaints, mild cognitive impairment, and dementia, the use of blood biomarkers, specifically, phosphorylated tau 217 and amyloid-beta 42/40 ratios, improved the diagnostic accuracy for pathological Alzheimer’s disease in primary care patients as well as patients seen by dementia specialists.
-
Blood Biomarkers for the Diagnosis of Alzheimer’s Disease
In this population-based study of patients in Sweden with cognitive complaints, mild cognitive impairment, and dementia, the use of blood biomarkers, specifically, phosphorylated tau 217 and amyloid-beta 42/40 ratios, improved the diagnostic accuracy for pathological Alzheimer’s disease in primary care patients as well as patients seen by dementia specialists.
-
Anchoring Alzheimer’s Disease Along an Amyloid Timeline
In 601 individuals from Wisconsin-based cohorts with amyloid-beta and tau positron emission tomography scans, the magnitude and topographical spread of tau pathology increased with longer duration of amyloid-beta positivity, and the cognitive decline was steepest in those with the longest duration of amyloid-beta positivity and elevated entorhinal tau.
-
Anchoring Alzheimer’s Disease Along an Amyloid Timeline
In 601 individuals from Wisconsin-based cohorts with amyloid-beta and tau positron emission tomography scans, the magnitude and topographical spread of tau pathology increased with longer duration of amyloid-beta positivity, and the cognitive decline was steepest in those with the longest duration of amyloid-beta positivity and elevated entorhinal tau.
-
Donanemab-azbt (Kisunla)
The U.S. Food and Drug Administration has approved the third anti-amyloid beta monoclonal antibody for the treatment of Alzheimer’s disease, following aducanumab and lecanemab.
-
An Updated Review on Metabolic Regulation in the Alzheimer’s Brain: Type 3 Diabetes?
Diabetes is a strong risk factor for the development of Alzheimer's disease (AD) given the mitochondrial, vascular, and inflammatory modalities that contribute to its progression. Therefore, it is vital to understand the pathophysiology of these two diseases as they relate to insulin resistance and mitochondrial dysfunction. Exposing a metabolic relationship between these diseases can provide further understanding of metabolic health and how treatment of insulin resistance can decrease disease burden.
-
Intensive Lifestyle Interventions May Prevent and Ameliorate the Symptoms of Alzheimer’s Disease
Recent clinical studies support the benefit of intensive lifestyle interventions, which should include a plant-based diet, exercise, stress management, and avoidance of smoking and alcohol, for the prevention of Alzheimer’s disease.
-
H. pylori Infection: A Warning Sign for Alzheimer’s Dementia
A large nested case-control cohort study of subjects aged 50 years and older found that clinically apparent Helicobacter pylori infection is associated with a moderately increased risk of developing Alzheimer’s disease.